Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | IL1B | P01584 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17197939 | 0.86 | CRBN (0.45) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL22940384 | 0.84 | CRBN (0.62) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL9988681 | 0.84 | DDB1 (0.60) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL12809078 | 0.84 | CRBN (0.51) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL21341598 | 0.84 | CRBN (0.43) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL21062845 | 0.83 | CRBN (0.60) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL21196697 | 0.83 | DDB1 (0.60) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL32679446 | 0.83 | CRBN (0.60) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL29589619 | 0.83 | CRBN (0.59) | CRBNDDB1IKZF3TSHRALDH1A1 | |
| SCHEMBL21331544 | 0.83 | CRBN (0.59) | CRBNDDB1TSHRALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027003-A | PROTAC compound, preparation method thereof and application of PROTAC compound as estrogen receptor degradation agent | 山东大学 | 2024-05-14 | — | — | CN | claimed |
| CN-117836299-A | Novel bifunctional heterocyclic compounds with Bruton tyrosine kinase decomposition via ubiquitin proteasome pathway and uses thereof | 韩国化学研究院 | 2024-04-05 | — | — | CN | claimed |
| WO-1992014455-A1 | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES | THE ROCKEFELLER UNIVERSITY (US) | 1992-09-03 | — | — | WO | claimed |
| CN-122029163-A | Chemical for targeting chromatin remodeling complexes and uses thereof | 丹娜-法伯癌症研究院 | 2026-05-12 | — | — | CN | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250368640-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-12-04 | — | — | US | disclosed |
| EP-4629981-A2 | SMALL MOLECULE DEGRADERS OF C-SRC KINASE | The Regents Of The University Of Michigan (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4540246-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-04-23 | — | — | EP | disclosed |
| CN-119751533-A | Estrogen receptor protein targeted degradation chimeric derivative based on estratriene structure, and preparation method and application thereof | 山东大学 | 2025-04-04 | — | — | CN | disclosed |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | Hinova Pharmaceuticals, Inc. (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-1903873-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | THE UNIVERSITY OF ROCHESTER (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080070303-A1 | Using myocardial and/or muscle progenitor cells as modeling tool in tissue engineering; regenerative medicine and organ replacement | ADVANCED CELL TECHNOLOGY | 2008-03-20 | — | — | US | disclosed |
| EP-1853302-A2 | ANTIANGIOGENIC AGENTS WITH ALDESLEUKIN | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20070197791-A1 | Method for the preparation of dicarboxylic lmides | SIEGFRIED LTD. (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070021464-A1 | Methods and compositions for inhibition of angiogenesis with EM-12 Derivatives | D AMATO ROBERT | 2007-01-25 | — | — | US | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006089150-A2 | ANTIANGIOGENIC AGENTS WITH ALDESLEUKIN | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| WO-1992014455-A1 | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES | THE ROCKEFELLER UNIVERSITY (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | CRBN 1/4885DDB1 2979/4885IKZF3 80/4885 |
| US-20250127903-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | CRBN 77/4885DDB1 769/4885IKZF3 2159/4885 |
| US-20250368640-A1 | MULTIPLE KINASE DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | MAP4K1, MAP4K4, MAP4K5 | CRBN 1379/4885DDB1 1741/4885IKZF3 1428/4885 |
| US-20250051347-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | AR, ADRM1, MDM2 | CRBN 619/4885DDB1 2893/4885IKZF3 755/4885 |
| US-20070197791-A1 | Method for the preparation of dicarboxylic lmides | RPL3, CCNH, CCNB3 | CRBN 17/4885DDB1 2008/4885IKZF3 1533/4885 |
| US-20070021464-A1 | Methods and compositions for inhibition of angiogenesis with EM-12 Derivatives | EDF1, FLT4, EML4 | CRBN 272/4885DDB1 412/4885IKZF3 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.